• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


Takeda Pharmaceuticals Expands Los Angeles, California, Operations

Takeda Pharmaceuticals, a patient-focused, R&D-driven global biopharmaceutical company, plans to expand operations in Los Angeles, California. The $230 million project is expected to create 125 jobs.

The investment will enable the company to meet the growing demand for plasma-derived therapies for people with rare, chronic and genetic diseases, such as immunodeficiencies and bleeding disorders.

“We are pleased to make this investment at our LA site, demonstrating our commitment to our manufacturing footprint in the U.S.,” said Thomas Wozniewski, global manufacturing & supply officer at Takeda. “The U.S. is playing a critical role in our global manufacturing network and contributing to our supply chain resilience globally. The new facility will provide additional plasma fractionation capacity of up to 2 million litres per year enabling us to produce more plasma-derived therapies for patients in need.”

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company and the third largest pharmaceutical company in Asia. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines.

“Global demand for plasma-derived therapies has increased over the past 20 years, and continues to grow due to increasing diagnosis rates, improvements in standard of care and broader access to treatment across more countries." noted Giles Platford, president, plasma derived therapies at Takeda. “The Los Angeles expansion will support us in serving more patients with life-transforming therapies and help them live a better life.”

Exclusive Research